Managing Pediatric Patients with Psoriasis

Abstract

Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. InEurope, etanercept has recently been approved for children aged 8 years and over. Data froma well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the initiation of treatment. Etanercept iswell tolerated; adverse effects are typically mild to moderate in severity. Early data from other biological agents are promising.

This is a preview of subscription content, log in to check access.

Table I
Table II

References

  1. 1.

    Sukhatme SV, Gottlieb AB. Pediatric psoriasis: updates in biologic therapies. Dermatol Ther 2009; 22: 34–9

    PubMed  Article  Google Scholar 

  2. 2.

    Marcoux D, Prost Y. Pediatric psoriasis revisited. J Cutan Med Surg 2002; 6 (3 Suppl.): 22–8

    PubMed  Article  Google Scholar 

  3. 3.

    Duffin KC, Krueger GG. Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol 2009; 129: 827–33

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Cordoro KM. Management of childhood psoriasis. Adv Dermatol 2008; 24: 125–69

    PubMed  Article  Google Scholar 

  5. 5.

    EPARs for authorised medicinal products for human use. Enbrel. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrelM2.htm

  6. 6.

    Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Demiatol 2003; 49: 171–82

    Article  Google Scholar 

  7. 7.

    Pasic A, Ceovic R, Lipozencic J, et al. Phototherapy in pediatric patients. Pediatr Dermatol 2003; 20: 71–7

    PubMed  Article  Google Scholar 

  8. 8.

    Herbst RA, Hoch O, Kapp A, et al. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol 2000; 42: 885–7

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Hawrot AC, Metry DW, Theos AJ, et al. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol 2006; 23: 67–71

    PubMed  Article  Google Scholar 

  10. 10.

    Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241–51

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology 2006; 213: 350–2

    PubMed  Article  Google Scholar 

  12. 12.

    FDA: CancerWarnings Required for TNF Blockers. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm

Download references

Acknowledgments

Editorial assistance for the preparation of this manuscript was provided by Stephanie Blick of inScience Communications. This assistance was funded by Pfizer. The authors report no conflicts of interest.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Lawrence A. Schachner.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bard, S., Torchia, D. & Schachner, L.A. Managing Pediatric Patients with Psoriasis. AM J Clin Dermatol 11, 15–17 (2010). https://doi.org/10.2165/1153415-S0-000000000-00000

Download citation

Keywords

  • Psoriasis
  • Infliximab
  • Etanercept
  • Juvenile Rheumatoid Arthritis
  • Plaque Psoriasis